1. INTRODUCTION:

Cervical cancer remains a major public health concern, particularly in low- and middle-income countries, where it is a leading cause of cancer-related mortality among women.¹ Persistent infection with high-risk Human Papillomavirus (HPV) types—especially HPV-16 and HPV-18—is responsible for approximately 70% of cervical cancer cases globally.²Adolescent girls constitute the primary target population for HPV vaccination programs because immunization prior to HPV exposure offers optimal protection. Vaccination during early adolescence not only prevents HPV infection but also contributes substantially to long-term reductions in cervical cancer incidence and mortality.³

2. Epidemiology of HPV Infection in Adolescent Girls:

HPV infection is commonly acquired soon after the onset of sexual activity. Epidemiological studies consistently demonstrate that adolescents and young women have the highest prevalence of HPV infection compared to other age groups. Although the majority of HPV infections are transient and resolve spontaneously, persistent infection with high-risk HPV strains can progress to cervical intraepithelial neoplasia and invasive cervical cancer later in life.⁴

Early adolescence therefore represents a strategic period for preventive intervention, as vaccination before sexual debut ensures protection prior to potential viral exposure.⁵

3. Rationale for HPV Vaccination During Adolescence:

3.1 Immunological Advantage:

Adolescent girls generate a stronger immune response to HPV vaccines than older adolescents and adults. Higher antibody titers achieved in younger age groups allow for durable protection, even with reduced-dose schedules.⁶

3.2 Vaccination Before Sexual Debut:

HPV vaccines are prophylactic rather than therapeutic. Consequently, vaccination is most effective when administered prior to exposure to HPV, making the 9–14-year age group ideal.⁷

3.3 Long-Term Cancer Prevention:

By preventing high-risk HPV infection early in life, vaccination interrupts the natural history of HPV infection and cervical carcinogenesis, thereby substantially reducing lifetime cervical cancer risk.⁸

4. HPV Vaccines and Recommended Schedules:

4.1 Types of HPV Vaccines

Currently available HPV vaccines include bivalent (HPV-16, HPV-18), quadrivalent (HPV-6, HPV-11, HPV-16, HPV-18), and nonavalent (HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-45, HPV-52, HPV-58) formulations.⁹

4.2 Recommended Vaccination Schedule:

Girls aged 9–14 years are recommended a two-dose schedule (0 and 6–12 months), while girls aged ≥15 years or immunocompromised individuals require a three-dose schedule (0, 1–2, and 6 months).¹⁰

5. Effectiveness of HPV Vaccination:

Randomized controlled trials and real-world observational studies have demonstrated that HPV vaccination is highly effective in preventing HPV-16 and HPV-18 infections, high-grade cervical intraepithelial neoplasia (CIN 2/3), and genital warts (with quadrivalent and nonavalent vaccines). Countries achieving high vaccination coverage have reported substantial reductions in HPV prevalence and precancerous cervical lesions among adolescent cohorts, confirming both individual- and population-level benefits.¹¹

6. Global HPV Vaccination Coverage and Progress (2024–2025):

6.1 Global Coverage Trends:

Global first-dose HPV vaccine coverage among girls aged 9–14 years reached approximately 31% in 2024, increasing from ~27% in 2023. As of 2025, 147–148 WHO Member States have introduced HPV vaccination into national immunization programs, and approximately 67 countries have adopted single-dose HPV vaccination schedules.¹²

6.2 Programmatic and Gavi-Supported Progress

HPV vaccine coverage in Gavi-supported countries increased substantially between 2019 and 2024, with millions of girls vaccinated annually and significant projected reductions in cervical cancer mortality.¹³

7. India-Specific Context: HPV Vaccination Among Adolescent Girls:

India bears a substantial share of the global cervical cancer burden, reporting approximately 123,000 new cases and 77,000 deaths annually. Prior to national rollout, HPV vaccine uptake remained extremely low, but phased inclusion under the Universal Immunization Programme (UIP) and adoption of the indigenous quadrivalent vaccine (Cervavac) represent major policy advances. Modeling studies suggest that nationwide adolescent vaccination could prevent nearly one million future cervical cancer cases.¹⁴

8. Safety of HPV Vaccines:

Extensive post-licensure surveillance confirms that HPV vaccines are safe, with most adverse events being mild and transient. No causal associations have been established with infertility, autoimmune disorders, or serious neurological conditions.¹

9. Impact of HPV Vaccination on Women’s Health:

HPV vaccination significantly reduces the incidence of high-grade cervical lesions, lowers healthcare costs associated with cancer treatment, reduces psychosocial stress related to abnormal screening results, and contributes to improved educational and economic participation among women.²

10. Barriers to HPV Vaccination:

Vaccination coverage remains suboptimal due to limited awareness, parental hesitancy, cultural misconceptions, cost barriers, and logistical challenges in delivery systems.³

11. Strategies to Improve Vaccine Uptake:

Expansion of school-based programs, strong healthcare provider recommendations, community engagement, policy integration, and mass media campaigns are critical strategies to improve vaccination uptake.⁴

12. Role of Nurses and Healthcare Professionals:

Nurses and frontline healthcare workers play a central role in vaccine advocacy, administration, counseling, surveillance of adverse events, and strengthening adolescent immunization policies.⁵

13. Future Perspectives:

Emerging evidence supports simplified dosing schedules and gender-neutral vaccination strategies, which may accelerate progress toward cervical cancer elimination goals.⁶

14. CONCLUSION:

HPV vaccination among adolescent girls is a scientifically validated, safe, and cost-effective intervention for preventing cervical cancer and improving long-term women’s health outcomes. Strengthening adolescent vaccination programs is essential to reducing global and national disparities in cervical cancer burden.⁷

15. REFERENCES:

1. Harper, D. M., et al. (2025). Impact of human papillomavirus vaccines in the reduction of cervical cancer precursors and related outcomes: updated global evidence. PMC Article.

2. Islam, M. R. (2025). Recent advances in human papillomavirus vaccines and future directions. Journal of Clinical Virology.

3. Brotherton, J. M. L., et al. (2025). Global status of HPV vaccination two decades in: population impact and cervical cancer trends. International Journal of Public Health.

4. Ilic, I. (2025). Human papillomavirus vaccination coverage estimates among the primary target cohort (9–14 year old girls) in the world (2010–2024). Vaccines.

5. World Health Organization. (2025). Global HPV vaccination programs and coverage rates: A systematic review. PubMed.

6. Tippins, A., Mutamba, G., Boyd, E. M., Coy, K. C., and Kriss, J. L. (2024). Human papillomavirus vaccination coverage among adolescent girls aged 13–17 years — U.S. Affiliated Pacific Islands (2013–2023). MMWR Weekly.

7. Dessy, H., et al. (2026). Maximizing impact: lessons from early HPV vaccination for long term cervical cancer prevention. Journal of Public Health.

8. Harper, D. M., et al. Impact of Human Papillomavirus Vaccines in the Reduction of Cervical Cancer Precursors and Related Outcomes: Updated Global Evidence. PMC, 2025.

9. Islam, M. R. Recent Advances in Human Papillomavirus Vaccines and Future Directions. Journal of Clinical Virology. 2025.

10. Brotherton, J. M. L., et al. Global Status of HPV Vaccination Two Decades In: Population Impact and Cervical Cancer Trends. International Journal of Public Health. 2025.

11. Ilic, I. Human Papillomavirus Vaccination Coverage Estimates Among the Primary Target Cohort (9–14 Year Old Girls) in the World (2010–2024). Vaccines, 2025.

12. World Health Organization. Global HPV Vaccination Programs and Coverage Rates: A Systematic Review. PubMed. 2025.

13. Tippins, A., et al. Human Papillomavirus Vaccination Coverage Among Adolescent Girls Aged 13–17 Years — U.S. Affiliated Pacific Islands, 2013–2023. MMWR Weekly. 2024.

14. Dessy, H., et al. Maximizing Impact: Lessons From Early HPV Vaccination for Long Term Cervical Cancer Prevention. Journal of Public Health, 2026.

Received on 18.01.2026 Revised on 13.02.2026

Accepted on 07.03.2026 Published on 30.04.2026

Available online from May 02, 2026

Asian J. Nursing Education and Research. 2026;16(2):137-139.

DOI: 10.52711/2349-2996.2026.00028

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.

Human Papillomavirus (HPV) Vaccination among Adolescent Girls: Implications for Cervical Cancer Prevention and Women’s Health